Gut bacteria targeted to fight prostate cancer drug resistance
NCT ID NCT06616597
Summary
This study is testing whether adding one or two common medications (dexamethasone and metronidazole) to a standard prostate cancer drug (abiraterone) can help overcome drug resistance. It aims to help men whose metastatic prostate cancer has stopped responding to abiraterone. The idea is that bacteria in the gut might be producing hormones that fuel the cancer, and these added drugs may block that process.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.